



June 27, 2018

**BSE Limited**  
Corporate Service  
Department  
1st Floor, New Trading Ring  
Rotunda Building, P.J.Tower  
Dalal Street, Fort  
**Mumbai - 400 001**

**The National Stock Exchange of India Ltd.**  
Exchange Plaza, 5<sup>th</sup> Floor,  
Bandra Kurla Complex  
Bandra (E)  
**Mumbai – 400 051**

Dear Sirs,

Pursuant to the provisions of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that the Board of Directors of the Company has, at its meeting held today, decided to obtain approval of the shareholders of the Company through Postal Ballot for issuance of Redeemable Non-Convertible Debentures (NCDs) on private placement basis upto an amount of Rs. 350 Crore. The proposed issue has been rated AA Stable by CRISIL as compared to AA- Stable for earlier NCD issue of Rs. 495 Crore by India Ratings. The proceeds would be mainly utilised for repayment of the existing debt and to reduce the overall cost of borrowing.

The Board meeting commenced at 12.30 p.m. and concluded at 1.45 p.m.

We request you to take the same on record.

Thanking you,

Yours faithfully,  
For Jubilant Life Sciences Limited

Rajiv Shah  
Company Secretary

**A Jubilant Bhartia Company**

OUR VALUES



**Jubilant Life Sciences Limited**

1-A, Sector 16-A,  
Noida-201 301, UP, India  
Tel: +91 120 4361000  
Fax: +91 120 4234895-96  
www.jubl.com

Regd Office:  
Bhartiagram, Gajraula  
Distt. Amroha - 244 223,  
UP, India  
CIN : L24116UP1978PLC004624